QuickView for guanylate cyclase activator activity (biogroup)

1. Uveal melanomas with differential syntenin-1 expression and other clinical attributes
2. Expression data in the developing human retina at 19-20 weeks' gestation
3. L1000 CMAP - Neural progenitor NPC cells treated with small molecule perturbagens
4. L1000 CMAP - Neural progenitor NPC.CAS9 cells treated with small molecule perturbagens
5. L1000 CMAP - Hepatocellular carcinoma HEPG2 cells treated with small molecule perturbagens

There were no matches for guanylate cyclase activator activity

1. Study to Find the Highest Safe Dose of Soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 Admini…
2. A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable…
3. Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator
4. A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on P…
5. A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy /…